Nootropic Peptide Stack Research: Mapping Mechanisms Across Semax, Selank, Cerebrolysin, NAD+, and Dihexa

These five compounds target distinct cognitive biology pathways: BDNF production (Semax), anxiety/GABA modulation (Selank), exogenous neurotrophic factor delivery (Cerebrolysin), neuronal energy metabolism (NAD+), and HGF/c-Met-mediated synaptogenesis (Dihexa). Their non-redundancy means they could theoretically be studied in combination without major mechanistic overlap. This guide maps those mechanisms for research design context, with evidence tier context for each compound. For individual compound deep dives, see the linked guides throughout.

BDNF (brain-derived neurotrophic factor): The primary neurotrophin for synaptic plasticity, neuronal survival, and cognitive function. Elevated by Semax and Cerebrolysin through different mechanisms.

GABA-A: The main inhibitory receptor in the CNS. Modulated by Selank at an allosteric site, producing anxiolytic effects distinct from benzodiazepine-class agonism.

Neurotrophic factor: A class of proteins that support neuronal growth, survival, and differentiation. Includes BDNF, NGF, GDNF, and CNTF. Cerebrolysin contains peptide fragments of multiple neurotrophic factors.

HGF/c-Met: Hepatocyte growth factor and its receptor. In the CNS, HGF/c-Met signaling drives synaptogenesis and dendritic spine formation. Activated by Dihexa.

Synaptogenesis: Formation of new synaptic connections. Targeted by Dihexa through HGF/c-Met; supported by BDNF through TrkB signaling.

NAD+ (nicotinamide adenine dinucleotide): The primary electron carrier in mitochondrial energy production. Also a substrate for sirtuins (SIRT1-7) involved in longevity and gene regulation. Declines with age.

Mitochondrial: Relating to mitochondria, the cellular organelles that produce ATP through oxidative phosphorylation. Neuronal function is highly dependent on mitochondrial output.

Monoamine: A class of neurotransmitters including dopamine, serotonin, and norepinephrine. Modulated by Semax through its effects on dopaminergic and serotonergic pathways.

Cognitive function emerges from the interaction of multiple biological subsystems. The major research-targetable nodes include: synaptic plasticity (BDNF/TrkB and HGF/c-Met pathways), neurotransmitter balance (monoamines, GABA, glutamate), neurotrophic support (BDNF, NGF, GDNF), neuronal energy metabolism (NAD+, mitochondrial ATP), and anxiety/stress regulation (HPA axis, GABA-A, enkephalin system).

Most single compounds primarily target one or two of these nodes. The scientific interest in multi-compound cognitive research design comes from the theoretical possibility of addressing multiple nodes simultaneously with compounds that do not significantly compete at the same molecular targets.

The five compounds reviewed here were selected because they represent distinct primary mechanisms across this network, making them the most commonly discussed combination in cognitive peptide research literature. No suggestion is made that combining them is safe, beneficial, or established practice for human use.

Semax: An ACTH 4-10 fragment analog that upregulates BDNF and NGF in hippocampal and prefrontal cortical circuits, modulates dopaminergic and serotonergic transmission, and provides neuroprotection in ischemic models. Primary research applications: cognitive enhancement, neuroprotection, stroke rehabilitation. See the Semax guide.

Selank: A tuftsin analog that modulates GABA-A receptors allosterically and inhibits enkephalin-degrading enzymes, producing anxiolytic effects without sedation. Secondary BDNF elevation occurs through reduced stress-axis suppression. Primary research applications: anxiety, stress regulation, cognitive rescue in anxious populations. See the Selank guide.

Cerebrolysin: A porcine brain-derived hydrolysate containing active peptide fragments of BDNF, NGF, GDNF, and CNTF. Delivers exogenous neurotrophic factor activity directly. Primary research applications: neurorecovery, Alzheimer's disease, TBI, stroke. See the Cerebrolysin guide.

NAD+: The fundamental mitochondrial electron carrier and sirtuin substrate. Supports neuronal ATP production, promotes SIRT1-mediated neuroprotective gene expression, and activates PARP DNA repair pathways. Primary research applications: aging biology, mitochondrial function, metabolic health. See the NAD+ guide.

Dihexa: A synthetic hexapeptide that potentiates HGF/c-Met signaling, driving synaptogenesis and dendritic spine formation in the hippocampus and cortex. Primary research applications: cognitive impairment models, HGF/c-Met pathway biology. See the Dihexa guide.

A structured comparison of how each compound maps onto the major cognitive biology pathways:

This map shows that each compound has a unique "fingerprint" across these pathways. No two compounds share the same primary mechanism. Where compounds share a downstream outcome (BDNF elevation), they achieve it through different upstream routes (Semax via ACTH receptor; Selank via stress axis; Cerebrolysin via direct delivery).

Designing research studies that examine multiple cognitive compounds requires attention to several methodological considerations. Mechanistic redundancy assessment: researchers should verify that the compounds under study do not share primary mechanisms, to avoid interpreting a pharmacodynamic interaction as a genuine synergy. The mechanism map above suggests minimal primary redundancy among these five.

Dosing and timing: each compound has distinct pharmacokinetic properties. Cerebrolysin is typically studied as an IV or IM administration course; Semax and Selank are intranasal; NAD+ is often studied as IV infusion or oral precursor. These different routes and half-lives require coordinated research scheduling. See peptide half-life explained and peptide administration routes for relevant pharmacokinetic context.

Endpoint selection: multi-compound cognitive studies require endpoints sensitive enough to detect mechanism-specific changes. A global cognitive battery may not differentiate BDNF-mediated improvements from anxiety-reduction-mediated improvements. Published multi-compound cognitive research typically uses mechanism-targeted endpoints alongside global performance measures.

Controls and blinding: multi-compound studies face greater complexity in active control design. Each individual compound should ideally have been characterized alone before combination studies are designed, to establish the baseline individual effects against which combination effects are measured.

Understanding what evidence exists for each compound is essential for research planning:

Cerebrolysin: Phase 2/3 RCT data in TBI, stroke, Alzheimer's disease, and vascular dementia. The highest evidence level of the five compounds in clinical settings. Approved in multiple countries.

Semax: Multiple published Russian-registered clinical trials in stroke, optic nerve injury, and cognitive recovery. Phase 2 equivalent evidence in Russian regulatory framework. No FDA-recognized Phase 3 data.

Selank: Multiple published Russian-registered clinical trials in anxiety and stress disorders. Comparable evidence tier to Semax within the Russian regulatory data set. No FDA-recognized Phase 3 data.

NAD+: Multiple published human pharmacokinetics, bioavailability, and aging biology trials. NAD+ precursor (NMN, NR) human data is more extensive than IV NAD+ clinical data. Mechanistic evidence is strong; outcome-level clinical efficacy data is still accumulating.

Dihexa: Preclinical animal model data only. No published human clinical trials. Lowest translational confidence of the five compounds.

For comprehensive evidence reviews, see: Cerebrolysin clinical evidence, Semax clinical evidence review, NAD+ longevity trial review, Dihexa HGF/c-Met research.

All compounds in this guide are research-only compounds in most regulatory jurisdictions. Cerebrolysin is approved in certain countries (Eastern Europe, Asia) for specific clinical indications. Semax and Selank are approved in Russia. Dihexa and NAD+ (as a standalone injectable) are not approved for human therapeutic use in the US or EU.

Multi-compound research designs involving these agents require institutional research oversight, IRB approval for any human subjects research, and compliance with applicable pharmacological research regulations. This guide is provided for research education and research design context only. It does not constitute a protocol for any human use.

For compound quality specifications relevant to research use, see the how to read a COA and storage and handling guides. For administration context, see peptide administration routes and how to reconstitute peptides.

For researchers building a comprehensive understanding of cognitive peptide biology, the Blackwell research library covers each compound in depth. Individual guides: Semax, Selank, Cerebrolysin, NAD+, Dihexa. Comparison articles: Cognitive peptides compared, Semax vs Selank comparison. Context guides: BDNF neuroplasticity explained, Peptides for brain health, Neuroprotection peptide research, Peptides for TBI research.